Furthermore, tumor cells that develop resistance to anti-HER2 therapies exhibit the upregulation of ER, and clinical trials have shown that TPBC demonstrates a lower response to anti-HER2 therapies compared to HER2-positive-only breast cancer cells [131]. The gene discussed is ESR1; the disease is breast carcinoma.